AM has a higher probability of being mutated in KIT and CDK 4/6, and a recent study showed that 20% of patients in a phase II clinical trial of Palbociclib for AM with CDK pathway mutations had tumor shrinkage3, another phase II clinical trial shows Imatinib ineffective in KIT-mutated AM4. This evidence concerns the gene KIT and neoplasm.